Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yuna | - |
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Lee, Jae Seung | - |
dc.contributor.author | Jeon, Mi Young | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Kim, Seung Up | - |
dc.date.accessioned | 2022-03-04T11:40:37Z | - |
dc.date.available | 2022-03-04T11:40:37Z | - |
dc.date.created | 2021-12-07 | - |
dc.date.issued | 2021-03-16 | - |
dc.identifier.issn | 0735-7907 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137736 | - |
dc.description.abstract | Transarterial radioembolization (TARE) is one of the therapeutic options for hepatocellular carcinoma (HCC). This study aimed to investigate the predictors and prognostic values of achieving curative treatments after TARE. Overall, 143 patients with intrahepatic HCC treated with TARE between 2011 and 2017 were recruited from two Korean tertiary institutes. Twenty-seven patients received curative treatments after TARE. Younger age than 65 years and AFP of <= 200 ng/mL independently predicted the increased probability of achieving curative treatment after TARE, and the curative treatment after TARE provided a survival benefit in patients with intrahepatic HCC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS INC | - |
dc.title | Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.identifier.doi | 10.1080/07357907.2020.1870126 | - |
dc.identifier.scopusid | 2-s2.0-85099382493 | - |
dc.identifier.wosid | 000606954000001 | - |
dc.identifier.bibliographicCitation | CANCER INVESTIGATION, v.39, no.3, pp.274 - 283 | - |
dc.relation.isPartOf | CANCER INVESTIGATION | - |
dc.citation.title | CANCER INVESTIGATION | - |
dc.citation.volume | 39 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 274 | - |
dc.citation.endPage | 283 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordAuthor | TARE | - |
dc.subject.keywordAuthor | Yttrium-90 | - |
dc.subject.keywordAuthor | curative treatment | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | radioembolization | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.